CD34+ 造血干细胞在阿尔茨海默病中的计数:一个元分析
Vinay Suresh1, Malavika Rudrakumar2, Anmol Kaur3
1King George's Medical University, Lucknow 226003, India.
Diseases (Basel, Switzerland)
|February 25, 2025
概括
阿尔茨海默病患者可能增加了CD34+造血干细胞. 然而,显著的研究变异和潜在的偏见意味着需要更多的研究来得出关于这些干细胞的确切结论.
科学领域:
- 神经科学是一个神经科学.
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- CD34+细胞是造血干细胞,对于血液细胞再生至关重要.
- 干细胞在阿尔茨海默氏症发病过程中的作用仍然是一个活跃的研究领域.
研究的目的:
- 在阿尔茨海默氏病 (AD) 患者中进行元分析,评估CD34+造血干细胞的数量.
- 为了比较AD患者和健康对照者之间的CD34+细胞计数.
主要方法:
- 系统的文献搜索观察性和干预性研究报告AD患者CD34+细胞计数.
- 使用常见和随机效应模型来计算标准化平均差异 (SMD) 的元分析.
- 评估异质性 (I2,p值) 和偏差风险 (纽卡斯尔-太华尺度,ROBINS-I).
主要成果:
- 包括5项涉及271名参与者的研究 (139名AD患者,132名对照).
- 一种常见的效应模型表明,在阿尔茨海默病患者中,CD34+细胞的适度增加 (SMD=0.2964).
- 一个随机效应模型显示非显著的增加 (SMD=0.2326),观察到实质性的异质性 (I2=87.1%,p<0.0001).
结论:
- 初步发现表明,与对照人群相比,阿尔茨海默氏症患者的循环CD34+细胞数量可能更高.
- 包含的研究中的显著异质性和潜在偏差限制了这些结论的确定性.
- 需要进一步进行高质量的研究,以澄清CD34+细胞在阿尔茨海默病中的作用.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.6K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147
